anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking.
METHODS: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital's emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed.
RESULTS: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737-0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis.
CONCLUSION: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
The invention discloses a preparation technology of a high-content compound herba houttuyniae mixture. According to the invention, herba houttuyniae, radix scutellariae, radix isatidis, fructus forsythia and honeysuckle are used as main medicinal materials to prepare the high-content compound herba houttuyniae mixture. The mixture contains the following active medicinal components: 10-25 micrograms/ml of houttuynin, 50-100 micrograms/ml of quercitrin, 1-2 mg/ml of baicalin and 15-40 micrograms/ml of forsythin. The preparation technology comprises the following steps: (1) flash extraction; (2) steam distillation; (3) alcohol precipitation; (4) water precipitation; and (5) preparation of the mixture. By the preparation technology, contents of the active medicinal components such as houttuynin, quercitrin and the like in the compound herba houttuyniae mixture can be effectively increased. In addition, components such as polysaccharide, protein, tannin and the like in the medicinal materials can be removed. Thus, precipitates generated during selling and storing process are reduced, and stability and safety of the medicine are raised. Besides, the high-content compound herba houttuyniae mixture can effectively treat throat pain caused by wind-heat common cold and acute pharyngitis and tonsillitis if used separately.
(1) Background: Since older adults are more susceptible to dehydration and there is a lack of information on older athletes, this study observed a group of 12 male padel players in this age group (70.42 ± 3.50 years) to characterize their hydration habits, physiological demands, and psychological responses before and during a 90 min padel training (PT). (2) Methods: After approval from the Ethics Committee (CE/FCDEF-UC/00022023) and the provision of signed informed consent, participants' body mass, height, waist and hip circumferences, body mass index, waist-to-hip ratio, and waist-to-height ratio were measured. Habitual fluid intake was monitored by diary from the evening until before the PT; the subjects completed a Profile of Mood States questionnaire (POMS) and a satiety scale (SLIM). To assess hydration levels at different moments, we used a portable osmometer and an eight-point urine color chart and weighed the participants immediately before and after the PT. During the PT, heart rate (HR) and hydration were monitored. After the PT, subjects completed another POMS and SLIM. (3) Results: Subjects trained at 73.2 ± 12.3% of their maximum HR, with brief peaks at the anaerobic threshold or higher (130.00 ± 18.78 bpm). The mean urine osmolality indicated normal hydration or minimal dehydration. However, the urine color values indicated dehydration after the training. Subjects drank 438 mL of liquids at night, 333 mL before PT, and 900 mL during the PT, with a good repartition of the liquids. POMS and SLIM were not affected by the training. (4) Conclusions: Older male padel athletes achieved challenging yet safe training, staying within healthy intensity zones; their hydration patterns nearly met the recommendations for exercise and should be slightly increased.
Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
After being informed about the study, all patients give written informed consent and will undergo a 1-week screening period to determine eligibility for study entry. Patient who meet the eligibility requirements will be given clinical and instrumental assessments before the start of treatment (T0) after 3 weeks (T1), at the end of the treatment (T2) and after 6 months (T3). A training program of 4 weeks including 250 videos of every day actions has been developed. Videos includes transitive and intransitive actions. Each week has a five day program, each day is divided in three sessions, in each session there are observation and imitation and attentional questions. AOT is always performed in conjunction with the conventional rehabilitation program.
Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
Group A: In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). The intensity of the workout program will progressively rise in line with each participant's improved functional ability. Schroth exercises, which are based on kinesthetic and sensorimotor concepts, will include both passive and active posture autocorrection exercises that are performed frequently. Postural motor control will be enhanced by doing corrective motions repeatedly. Strength and endurance training of the postural muscles is another component of Schroth exercises therapy, which aims to enhance the curve, improve the patient's self-image, and lessen pain. Patients were positioned asymmetrically to optimize trunk rectification. The program will consist of activities designed to increase the curvature, muscle strength, and endurance of postural muscles. These exercises will include spinal elongation, de-flexion, stretching, de-rotation, and strengthening. To provide passive support and correct posture during the SET, long poles, foam blocks, and rice sacks were employed. Depending on how well the patient performs the exercises, the intensity of the Schroth exercises will be gradually raised by modifying the patient's position, varying the number of sets and repetitions of the exercises, and reducing the quantity or degree of passive support. Ten sessions total (30 minutes each, five days a week) will be conducted.

Group B: Group B will engage in independent routine physical therapy (RPT). Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. The patient will be actively taught standard upper extremity range-of-motion exercises. Without using any creams or lotions, myofascial release (MFR) procedures will be applied straight to the skin. To assist avoid back discomfort, pressure will be administered to the restricted area for 90-120 seconds in order to release the tissue. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. The same protocol will be followed for the cat and camel, double-leg abdominal presses, and superwoman exercises. There will be breathing exercises including thoracic expansion and diaphragmatic breathing.
The present invention provides aqueous formulations containing at least one cannabinoid, such as, for example, tetrahydrocannabinol (THC), cannabidiol (CBD), and a sulfoalkyl ether cyclodextrin (SAE-CD). The liquid formulations are substantially clear, sterilizable, and chemically and physically stable. The liquid formulations do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The SAE-CD-containing formulation provides significant advantages over other cyclodextrin-containing formulations of cannabinoids. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of at least one cannabinoid suitable for administration by injection. An SAE-CD-containing formulation of at least one cannabinoid can be provided in liquid form or as a reconstitutable solid. Solutions can be made either dilatable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.
BACKGROUND: A pancreatic duct rupture can lead to various complications such as a fistula, pseudocyst, ascites, or walled-off necrosis. Due to pleural effusion, pancreaticopleural fistula typically causes dyspnea and chest pain. Leaks of enzyme-rich pancreatic fluid forming a pleural effusion can be verified in a thoracocentesis following radiological imaging such as computed tomography or magnetic resonance tomography. While management strategies range from a conservative to endoscopic and surgical approach, we report a case with successful minimally invasive treatment of pancreaticopleural fistula and effusion.
CASE PRESENTATION: We present a case of a patient with pancreaticopleural fistula and successful minimally invasive surgical treatment. A 62-year old Caucasian man presented with acute chest pain and dyspnea. A computed tomography scan identified a left-sided cystoid formation, extending from the abdominal cavity into the left hemithorax with concomitant pleural effusion. Pleural effusion analysis indicated significantly elevated pancreatic enzymes. Magnetic resonance cholangiopancreatography revealed a rupture of the pancreatic duct and nearby fluid accumulation. Endosonography later confirmed proximity to the tail of the pancreas, suggesting a pancreatic pseudocyst with visible tract into the pancreas. We assumed a pancreatic duct rupture with a fistula from the tail of the pancreas transdiaphragmatically into the left hemithorax with a commencing pleural empyema. A visceral and parietal decortication on the left hemithorax and a laparoscopic distal pancreatectomy with splenectomy was performed. The suspected diagnosis of a fistula arising from the pancreatic duct was confirmed histologically.
CONCLUSION: Pancreaticopleural fistulas often have a long course and may remain undiagnosed for a long time. At this point diagnostic management and therapy demand a high level of expertise. In instances of unclear symptomatic pleural effusion, considering an abdominal focus is crucial. If endoscopic treatment is not feasible, minimally invasive surgery should strongly be considered, especially when located in the distal pancreas.
The investigators hypothesize that early mobility condition and muscle power may be the predictive factors for COVID-19 patients' activity prognosis and hospitalization days. To prove our hypothesis, the investigators checked the patient's baseline ICUMS and MRCSS upon admission. Also, blood test results were also obtained. Subsequently, the investigators measured their outcomes by Barthel index and hospitalization length, and divided them into two groups. The ICUMS, MRCSS and the blood test results differences between two groups were checked. For those factors that showed significant difference between two groups, the investigators recruited them into regression model. Last, receiver operating curve of those factors were plotted to find the appropriate cutoff points for identifying two groups of outcomes.
A traditional Chinese medicine preparation method for remedying the facial neuritis belongs to the technical field of traditional Chinese medicine preparation method. The treatment for the facial neuritis in the acute period aims at controlling infection, improving facial blood circulation and reducing facial nerve oedema. The strong relaxing-treatment has great side effect and toxicity, which is forbidden to be applied to the patients with diabetes, hypertension or ulcer disease in active stage and the patients with renal insufficiency. The technical proposal of the present invention is that giant typhonium rhizome, white mustard seed, Chinese honey locust, jackinthepulpit tuber, tall gastrodia rhizome, uncaria, tribulus terrestris, earthworm, stiff silkworm, scorpion, centipede, fineleaf schizonepeta, divaricate saposhnikovia root, asarum, dahurian angelica root, Chinese ligusticum rhizome, biond magnolia flower, ginger, incised notopterygium rhizome and root, medicinal evodia fruit and raw liquorice are put into 1000ml. of water to be soaked for 30 minutes and then decocted by slow fire, and the decocted medicinal liquid is filtered by a gauze for filtrating residues to obtain 520ml. of medicinal liquid, that is the traditional Chinese medicine for remedying the facial neuritis and has the advantages of easy manufacturing, little side effect and toxicity of the traditional Chinese medicinal liquid which is absorbed well in alimentary tract after being taken orally and has stable curative effect and does not cause recrudescence easily.
Patients receive letrozole PO QD. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole orally PO QD in the absence of disease progression or unacceptable toxicity as maintenance therapy. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.
FIELD: medicine.SUBSTANCE: invention relates to medicine and namely to traumatology. The spatial visualization of the affected pubic bones of the pelvis is carried out with the help of the method of multilayer spiral computed tomography during the preoperative period before surgical treatment. Magnetic resonance imaging is used to assess the state of the surrounding soft tissues, vascular and nerve structures which are not visualized when performing multilayer spiral computed tomography. The passive urinary diversion catheter is put into the bladder transurethrally after anesthesia is performed with a patient in the supine position and before the start of surgery. The symphysis is exposed by a suprasymphyseal transverse incision of the skin and an approach along the upper edge of the pubic joint to the fascia and to the bone, while the two rectus abdominis muscles are separated from their places of origin and shifted subperiosteally to the pubic tubercles. Then prevesical blunt finger detachment of the fascial plate is performed with its inward displacement with the anterior wall of the bladder. The affected areas of the pubic symphysis are resected using surgical nippers on both sides of the pubic bones to their healthy area. After that, without bringing the resected pubic bones closer to each other, a metal plate with holes for fixing screws, which is made in the shape of the pubic articulation bone in the form of a flat ring sector with rounded corners, is placed along the upper anterior edge of the pubic bones as an implant along the upper anterior edge of the pubic bones. After that 6 or 8 holes are made in the plate to accommodate fixing screws, the metal implant plate is fixed with 6 or 8 fixing screws, placing them in pre-made blind holes in the bones of the pubic articulation of the pelvic ring. The volume of the formed bone cavity of the post-resection defect of the pubic bones is filled with granules of osteoplastic biological material based on bone tissue impregnated with aqueous solutions of gentamicin with a concentration of 20-60 mg/ml and / or tobramycin with a concentration of 30-60 mg/ml. Then two drains are installed. One drain is installed in the rettium space and the second one is installed in front of the pubic joint. After the metal implant is placed in a correct position using a control X-ray of the pelvis, hemostasis control is ensured and layer-by-layer wound closure is performed.EFFECT: method ensures reliable anatomical restoration of the shape and support function of the pelvis with the simultaneous absence of multiplanar displacements of the fixed bones and provides sufficient preservation of a patient's motor activity in the early postoperative period. It also eliminates dyspareunia and normalizes the sexual function for women, ensures the absence of infectious lesions of the surrounding tissues with simultaneous preservation blood supply and innervation.2 cl, 5 ex
ONOO-, a bioactive molecule, plays a critical role in inflammation-related signaling pathways and pathological mechanisms. Numerous studies have established a direct correlation between elevated ONOO- levels and tumor progression. Therefore, investigating ONOO- levels in inflammation and tumors is of utmost importance. Fluorescence imaging presents a highly sensitive, non-invasive, easily operable, selective, and efficient method for ONOO- detection in situ. In this study, we designed and synthesized a rhodamine-based probe, NRho, which effectively identifies tumors, inflammatory cells, tissues, and organs by detecting ONOO- content. The synthesis process of NRho is simple, yielding a probe with favorable spectral characteristics and rapid response. Our cell imaging analysis has provided novel insights, revealing distinct ONOO- levels among different types of cancer cells, with hepatocellular carcinoma cells exhibiting higher ONOO- content than the others. This observation marks the proposal of such variations in ONOO- levels across cancer cell types. Furthermore, our study has showcased the practicality of our probe in live organ imaging, enabling the identification of tumors from living organs within a brief 5-minute incubation period. Additionally, our findings highlight the rapid detection capability of the probe NRho in various tissue samples, effectively identifying inflammation. This research holds important promise in advancing biomedical research and clinical diagnosis.
BACKGROUND: Venovenous extracorporeal membrane oxygenation (VV ECMO) has been widely used for severe acute respiratory distress syndrome (ARDS) in recent years. However, the role of hemoadsorption in ARDS patients requiring VV ECMO is unclear.
METHODS: Therefore, we conducted a systematic review to describe the effect of hemoadsorption on outcomes of ARDS patients requiring VV ECMO and elucidate the risk factors for adverse outcomes. We conducted and reported a systematic literature review based on the principles derived from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The systematic review searched Embase, CINHAL, and Pubmed databases for studies on ARDS patients receiving hemoadsorption and VV ECMO. The demographic data, clinical data and biological data of the patients were collected.
RESULTS: We ultimately included a total of 8 articles including 189 patients. We characterized the population both clinically and biologically. Our review showed most studies described reductions in inflammatory markers and fluid resuscitation drug dosage in ARDS patients with Coronavirus disease 2019 (COVID-19) or sepsis after hemoadsorption.
CONCLUSION: Because most of the studies have the characteristics of high heterogeneity, we could only draw very cautious conclusions that hemoadsorption therapy may enhance hemodynamic stability in ARDS patients with COVID-19 or sepsis receiving VV ECMO support. However, our results do not allow us to draw conclusions that hemoadsorption could reduce inflammation and mortality. Prospective randomized controlled studies with a larger sample size are needed in the future to verify the role of hemoadsorption in ARDS patients requiring VV ECMO.
The invention discloses a scheme for preparing some specific nanobody system and delivering nanobody medicine through woman's vagina as well as its preparation method and applications. Women's vagina is rich of capillaries and lymphatic vessels, vaginal permeability is greater than the rectum, mouth, and skin. Vaginal administration can not only local medication, but also systemic medication. Due to the unstable activity of traditional antibody or high molecular protein, large volume and other reasons, the biomedical administration mode is basically limited to the injection type. Nanobodies are the smallest units known to bind target antigens. The three-dimensional structure of nanobodies determines its relative stable biological activity, also nanobody has the characteristics of high temperature resistance, acid-base resistance, good water-solubility and strong tissue penetration. Thus, a wide range of applications of the Nanobody delivery system in disease treatment and women's health care can be achieved by optimizing carrier formulation to maintain and enhance the stability and tissue penetration of the nanobody, Vaginal nanobody formulations include: creams, crosslinked polyvinyl alcohol (PEG) hydrophilic gels, vaginal gels, vaginal capsules and tablets, vaginal suppositories, vaginal rings, and vaginal film. Nanobody vaginal administration can be used for specific nanobody in the local application, also can be used to penetrate the vaginal mucosa into the bloodstream to reach the preset lesion site to play a role. The vaginal delivery system includes specific nanobodies directly against different target sites of disease, such as local targets include: vaginal infections, endometriosis, uterine fibroids, and contraception, while systemic targets include inflammation and Rheumatism, cancer, viral bacteria, cardiovascular diseases, diabetes mellitus, Alzheimer's disease, but the target sites of the vaginal administration of the nanobody is not limited thereto. The composition for vaginal administration of the nanobody includes, but not limited to, soluble macromolecular glycogel matrix, polyethylene glycol (PEG), levoglucose, polyamino acid, glycerin, and stirring and mixing with optimized formulation of hydrolase inhibitor. The invention discloses a preparation method and application of a nanobody vaginal delivery system, a safe and effective administration model, develops a new form of nanobody biomedicine and has a wide application prospect.
Aripiprazole is an atypical antipsychotic medication which is currently approved for the treatment of schizophrenia in adults. Multiple clinical trials in both children and adults have shown the effectiveness in the treatment of autism with medications like Aripiprazole. This study aims at assessing the effect of aripiprazole vs. placebo treatment on symptoms of irritability and aggression associated with autism, as well as the effect on the global severity of child and adolescent autistic disorder. Children or adolescent outpatients, with age ranges from 5-17, will be enrolled into an 8-week placebo controlled, double blind treatment study. During the 8 weeks, patients will be monitored by the treating psychiatrist. Study assessments will be administered at designated time points.